Biovance Capital Partners
Venture capital
UncertainLast verified 7 Nov 2026
Portuguese life sciences VC investing in early-stage drug development and biotech startups across Europe, especially Southern Europe, targeting seed and Series A rounds.
0 deals in the last 24 months. Taken from its own website.
Key facts
- Stages
- Seed, Series A
- Sectors
- Biotech & pharma
- Ticket
- €1.5M–€6M
- Eligible countries
- Not stated
- Provider based in
- Portugal
- Timing
- Rolling applications
- Focus
- early-stage biotech; disruptive drug development; novel transformational therapies
- How to apply
- Apply route unknown
Recent deals
No deals in our data for the last 24 months.
Evidence
Short excerpts from the sources, in their original language, that back the facts above.
- Kind
Biovance Capital Partners, Portugal’s leading life sciences venture capital (VC) firm
https://biovancecapital.com/revolutionize-your-ride-ultimate-ev-charging-solutions - Sectors
Biovance Capital will invest in disruptive drug development companies across Europe.
https://biovancecapital.com/revolutionize-your-ride-ultimate-ev-charging-solutions - Stages
The investment team will target seed and Series A rounds
https://biovancecapital.com/revolutionize-your-ride-ultimate-ev-charging-solutions - Ticket
with ticket sizes ranging from € 1.5 to 6 million.
https://biovancecapital.com/revolutionize-your-ride-ultimate-ev-charging-solutions - Ticket
with ticket sizes ranging from € 1.5 to 6 million.
https://biovancecapital.com/revolutionize-your-ride-ultimate-ev-charging-solutions
Status history
- 7 Nov 2026: Rolling → Uncertain (freshness: investor activity)
- 6 Nov 2026: Rolling (first extraction)
Something wrong or out of date? Report an error.
Work at Biovance Capital Partners? Claim this profile to confirm what you invest in.